TJ Cradick
Chief Technology Officer HuidaGene Therapeutics
TJ Cradick PhD is the Chief Technology Officer (CTO) at HuidaGene Therapeutics, a global, clinical-stage biotech company that has developed a number of proprietary gene editing tools. TJ is a recognized leader and innovator in the field of CRISPR/Cas9 technology, having published several influential papers on its applications, mechanisms, and optimization. He is also a Scientific Advisory Board Member at Eucalyptus Bio (CRISP-HR Therapeutics, Inc.) and at Catalytic Data Science. TJ is passionate about advancing the science and practice of CRISPR/Cas9 to address unmet medical needs and transform the lives of patients.
Seminars
Developing clinically successful therapies with strong efficacy and tolerability relies on robust preclinical development and regulatory compliance in order to maximize patient safety and ultimately drive market success. Navigating the regulatory landscape for RNA editing can be challenging, with unforeseen hurdles to overcome on the path to commercialization.
This workshop will address:
• Understanding the attributes necessary for clinical translation of RNA editing candidates
• Navigating the regulatory path and upholding standards during preclinical and clinical development
• Identifying key hurdles on the path to commercialization and strategizing solutions to accelerate success in the clinic and on the market
